-
3
-
-
43949091796
-
Lung cancer epigenetics and genetics
-
Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer. 2008; 123: 1-7.
-
(2008)
Int J Cancer
, vol.123
, pp. 1-7
-
-
Risch, A.1
Plass, C.2
-
5
-
-
0033591845
-
Tobacco smoke carcinogens and lung cancer
-
Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999; 91: 1194-1210.
-
(1999)
J Natl Cancer Inst
, vol.91
, pp. 1194-1210
-
-
Hecht, S.S.1
-
6
-
-
4444344330
-
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
-
Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004; 101: 13306-13311.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 13306-13311
-
-
Pao, W.1
Miller, V.2
Zakowski, M.3
-
7
-
-
2342624080
-
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
-
Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500.
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Jänne, P.A.2
Lee, J.C.3
-
8
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
9
-
-
13844317894
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
-
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786-792.
-
(2005)
N Engl J Med
, vol.352
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
-
10
-
-
18244371651
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLos Med. 2005; 2: e73.
-
(2005)
PLos Med
, vol.2
-
-
Pao, W.1
Miller, V.A.2
Politi, K.A.3
-
11
-
-
20444480258
-
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers
-
Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005; 65: 5076-5083.
-
(2005)
Cancer Res
, vol.65
, pp. 5076-5083
-
-
Le Calvez, F.1
Mukeria, A.2
Hunt, J.D.3
-
12
-
-
15744372810
-
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
-
Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005; 2: e17.
-
(2005)
PLoS Med
, vol.2
-
-
Pao, W.1
Wang, T.Y.2
Riely, G.J.3
-
13
-
-
54549094903
-
Somatic mutations affect key pathways in lung adenocarcinoma
-
Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455: 1069-1075.
-
(2008)
Nature
, vol.455
, pp. 1069-1075
-
-
Ding, L.1
Getz, G.2
Wheeler, D.A.3
-
14
-
-
21344437734
-
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis
-
Zhao X, Weir BA, LaFramboise T, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 2005; 65: 5561-5570.
-
(2005)
Cancer Res
, vol.65
, pp. 5561-5570
-
-
Zhao, X.1
Weir, B.A.2
LaFramboise, T.3
-
15
-
-
33845191779
-
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
-
Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006; 10: 529-541.
-
(2006)
Cancer Cell
, vol.10
, pp. 529-541
-
-
Chin, K.1
DeVries, S.2
Fridlyand, J.3
-
16
-
-
79953737554
-
A new treasure in breast cancer gene hunt
-
Spellman P, Gray J. A new treasure in breast cancer gene hunt. Nat Med. 2011; 17: 422-423.
-
(2011)
Nat Med
, vol.17
, pp. 422-423
-
-
Spellman, P.1
Gray, J.2
-
17
-
-
3543023204
-
Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification
-
Schouten JP, McElgunn CJ, Waaijer R, et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002; 30: e57.
-
(2002)
Nucleic Acids Res
, vol.30
-
-
Schouten, J.P.1
McElgunn, C.J.2
Waaijer, R.3
-
18
-
-
1642286979
-
Chromosomal analysis of non-small-cell lung cancer by multicolor fluorescent in situ hybridization
-
Berrieman HK, Ashman JN, Cowen ME, et al. Chromosomal analysis of non-small-cell lung cancer by multicolor fluorescent in situ hybridization. Br J Cancer. 2004; 90: 900-5.
-
(2004)
Br J Cancer
, vol.90
, pp. 900-905
-
-
Berrieman, H.K.1
Ashman, J.N.2
Cowen, M.E.3
-
19
-
-
0035026584
-
Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization
-
Luk C, Tsao MS, Bayani J, Shepherd F, Squire JA. Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet. 2001; 125: 87-99.
-
(2001)
Cancer Genet Cytogenet
, vol.125
, pp. 87-99
-
-
Luk, C.1
Tsao, M.S.2
Bayani, J.3
Shepherd, F.4
Squire, J.A.5
-
20
-
-
0344734060
-
DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma
-
Björkqvist AM, Husgafvel-Pursiainen K, Anttila S, et al. DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer. 1998; 22: 79-82.
-
(1998)
Genes Chromosomes Cancer
, vol.22
, pp. 79-82
-
-
Björkqvist, A.M.1
Husgafvel-Pursiainen, K.2
Anttila, S.3
-
21
-
-
0026495364
-
Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors
-
Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992; 258: 818-821.
-
(1992)
Science
, vol.258
, pp. 818-821
-
-
Kallioniemi, A.1
Kallioniemi, O.P.2
Sudar, D.3
-
22
-
-
0031442680
-
Detailed deletion mapping at chromosome 9p21 in non-small cell lung cancer by microsatellite analysis and fluorescence in situ hybridization
-
Okami K, Cairns P, Westra WH, et al. Detailed deletion mapping at chromosome 9p21 in non-small cell lung cancer by microsatellite analysis and fluorescence in situ hybridization. Int J Cancer. 1997; 74: 588-592.
-
(1997)
Int J Cancer
, vol.74
, pp. 588-592
-
-
Okami, K.1
Cairns, P.2
Westra, W.H.3
-
23
-
-
36248980204
-
Characterizing the cancer genome in lung adenocarcinoma
-
Weis BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007; 450: 893-898.
-
(2007)
Nature
, vol.450
, pp. 893-898
-
-
Weis, B.A.1
Woo, M.S.2
Getz, G.3
-
24
-
-
28544431712
-
Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers
-
Kim TM, Yim SH, Lee JS, et al. Genome-wide screening of genomic alterations and their clinicopathologic implications in non-small cell lung cancers. Clin Cancer Res. 2005; 11: 8235-8242.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 8235-8242
-
-
Kim, T.M.1
Yim, S.H.2
Lee, J.S.3
-
25
-
-
77957896015
-
Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer
-
Castro M, Grau L, Puerta P, et al. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med. 2010; 8: 86.
-
(2010)
J Transl Med
, vol.8
, pp. 86
-
-
Castro, M.1
Grau, L.2
Puerta, P.3
-
26
-
-
84923682707
-
-
Mitelman database of chromosome aberrations and gene fusions in cancer
-
Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations and gene fusions in cancer; 2009. http://cgap.nci.nih.gov/Chromosomes/Mitelman
-
(2009)
-
-
Mitelman, F.1
Johansson, B.2
Mertens, F.3
-
27
-
-
0033109539
-
Chromosome 8 copy numbers and the c-myc gene amplification in non-small cell lung cancer. Analysis by interphase cytogenetics
-
Kubokura H, Koizumi K, Yamamoto M, Tanaka S. Chromosome 8 copy numbers and the c-myc gene amplification in non-small cell lung cancer. Analysis by interphase cytogenetics. Nihon Ika Daigaku Zasshi. 1999; 66: 107-112.
-
(1999)
Nihon Ika Daigaku Zasshi
, vol.66
, pp. 107-112
-
-
Kubokura, H.1
Koizumi, K.2
Yamamoto, M.3
Tanaka, S.4
-
28
-
-
79952078260
-
ZNF703 gene amplification at 8p12 specifies luminal B breast cancer
-
Sircoulomb F, Nicolas N, Ferrari A, et al. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer. EMBO Mol Med. 2011; 3: 153-166.
-
(2011)
EMBO Mol Med
, vol.3
, pp. 153-166
-
-
Sircoulomb, F.1
Nicolas, N.2
Ferrari, A.3
-
29
-
-
79952093026
-
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium
-
Holland DG, Burleigh A, Git A, et al. ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med. 2011; 3: 167-180.
-
(2011)
EMBO Mol Med
, vol.3
, pp. 167-180
-
-
Holland, D.G.1
Burleigh, A.2
Git, A.3
-
30
-
-
84883159846
-
Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling
-
Zhang X, Mu X, Huang O, et al. Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling. PLoS One. 2013; 8: e72053.
-
(2013)
PLoS One
, vol.8
-
-
Zhang, X.1
Mu, X.2
Huang, O.3
-
31
-
-
84904300249
-
ZNF703 acts as an oncogene that promotes progression in gastric cancer
-
Yang G, Ma F, Zhang M, et al. ZNF703 acts as an oncogene that promotes progression in gastric cancer. Oncol Rep. 2014; 31: 1877-1882.
-
(2014)
Oncol Rep
, vol.31
, pp. 1877-1882
-
-
Yang, G.1
Ma, F.2
Zhang, M.3
-
32
-
-
84923068533
-
ZNF703 promotes tumor cell proliferation and invasion and predicts poor prognosis in patients with colorectal cancer
-
Ma F, Bi L, Yang G, et al. ZNF703 promotes tumor cell proliferation and invasion and predicts poor prognosis in patients with colorectal cancer. Oncol Rep. 2014; 32: 1071-1077.
-
(2014)
Oncol Rep
, vol.32
, pp. 1071-1077
-
-
Ma, F.1
Bi, L.2
Yang, G.3
-
33
-
-
84902110153
-
High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer
-
Reynisdottir I, Arason A, Einarsdottir BO, et al. High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer. Cancer Med. 2013; 2: 437-446.
-
(2013)
Cancer Med
, vol.2
, pp. 437-446
-
-
Reynisdottir, I.1
Arason, A.2
Einarsdottir, B.O.3
-
34
-
-
79952093753
-
Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization
-
Slorach EM, Chou J, Werb Z. Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization. Genes Dev. 2011; 25: 471-484.
-
(2011)
Genes Dev
, vol.25
, pp. 471-484
-
-
Slorach, E.M.1
Chou, J.2
Werb, Z.3
-
35
-
-
84861974512
-
The PRDM family: expanding roles in stem cells and development
-
Hohenauer T, Moore AW. The PRDM family: expanding roles in stem cells and development. Development. 2012; 139: 2267-2282.
-
(2012)
Development
, vol.139
, pp. 2267-2282
-
-
Hohenauer, T.1
Moore, A.W.2
-
36
-
-
84901190070
-
PRDM14: a unique regulator for pluripotency and epigenetic reprogramming
-
Nakaki F, Saitou M. PRDM14: a unique regulator for pluripotency and epigenetic reprogramming. Trends Biochem Sci. 2014; 39: 289-298.
-
(2014)
Trends Biochem Sci
, vol.39
, pp. 289-298
-
-
Nakaki, F.1
Saitou, M.2
-
37
-
-
35448972855
-
Gene amplification and overexpression of PRDM14 in breast cancers
-
Nishikawa N, Toyota M, Suzuki H, et al. Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res. 2007; 67: 9649-9657.
-
(2007)
Cancer Res
, vol.67
, pp. 9649-9657
-
-
Nishikawa, N.1
Toyota, M.2
Suzuki, H.3
-
38
-
-
57049188396
-
The zinc finger SET domain gene PRDM14 is overexpressed in lymphoblastic lymphomas with retroviral insertions at Evi32
-
Dettman EJ, Justice MJ. The zinc finger SET domain gene PRDM14 is overexpressed in lymphoblastic lymphomas with retroviral insertions at Evi32. PLoS One. 2008; 3: e3823.
-
(2008)
PLoS One
, vol.3
-
-
Dettman, E.J.1
Justice, M.J.2
-
39
-
-
77954242252
-
Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes
-
Moelans CB, de Weger RA, Monsuur HN, et al. Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol. 2010; 23: 1029-1039.
-
(2010)
Mod Pathol
, vol.23
, pp. 1029-1039
-
-
Moelans, C.B.1
de Weger, R.A.2
Monsuur, H.N.3
-
40
-
-
84871537455
-
Mouse lymphoblastic leukemias induced by aberrant Prdm14 expression demonstrate widespread copy number alterations also found in human ALL
-
Simko SJ, Voicu H, Carofino BL, et al. Mouse lymphoblastic leukemias induced by aberrant Prdm14 expression demonstrate widespread copy number alterations also found in human ALL. Cancers. 2012; 4: 1050-1066.
-
(2012)
Cancers
, vol.4
, pp. 1050-1066
-
-
Simko, S.J.1
Voicu, H.2
Carofino, B.L.3
-
41
-
-
84878721081
-
Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14
-
Ruark E, Seal S, McDonald H, et al. Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. Nat Genet. 2013; 45: 686-689.
-
(2013)
Nat Genet
, vol.45
, pp. 686-689
-
-
Ruark, E.1
Seal, S.2
McDonald, H.3
-
42
-
-
78049403613
-
Relationship between the expression of PRDM14 in non-small cell lung cancer and the clinicopathologic characteristics
-
Liu B, Zhang S, Hui L, et al. Relationship between the expression of PRDM14 in non-small cell lung cancer and the clinicopathologic characteristics. Zhongguo Fei Ai Za Zhi. 2010; 13: 867-872.
-
(2010)
Zhongguo Fei Ai Za Zhi
, vol.13
, pp. 867-872
-
-
Liu, B.1
Zhang, S.2
Hui, L.3
-
43
-
-
84892382521
-
High expression of PRDM14 correlates with cell differentiation and is a novel prognostic marker is resected non-small cell lung cancer
-
Zhang T, Meng L, Dong W, et al. High expression of PRDM14 correlates with cell differentiation and is a novel prognostic marker is resected non-small cell lung cancer. Med Oncol. 2013; 30: 605.
-
(2013)
Med Oncol
, vol.30
, pp. 605
-
-
Zhang, T.1
Meng, L.2
Dong, W.3
-
44
-
-
79960042810
-
Arf6 RalA and BIRC5 protein expression in non small cell lung cancer
-
Knizhnik AV, Kovaleva OB, Laktionov KK, et al. Arf6, RalA and BIRC5 protein expression in non small cell lung cancer. Mol Biol. (Mosk). 2011; 45: 307-315.
-
(2011)
Mol Biol. (Mosk).
, vol.45
, pp. 307-315
-
-
Knizhnik, A.V.1
Kovaleva, O.B.2
Laktionov, K.K.3
-
45
-
-
0043025147
-
Survivin gene expression in early stage non-small cell lung cancer
-
Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early stage non-small cell lung cancer. J Pathol. 2003; 200: 620-626.
-
(2003)
J Pathol
, vol.200
, pp. 620-626
-
-
Falleni, M.1
Pellegrini, C.2
Marchetti, A.3
-
46
-
-
84863365307
-
Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis
-
Zhang LQ, Wang J, Jiang F, et al. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLos One. 2012; 7: e34100.
-
(2012)
PLos One
, vol.7
-
-
Zhang, L.Q.1
Wang, J.2
Jiang, F.3
-
47
-
-
1842790378
-
c-Myc as a therapeutic target in cancer
-
Prochownik EV. c-Myc as a therapeutic target in cancer. Expert Rev Anticancer Ther. 2004; 4: 289-302.
-
(2004)
Expert Rev Anticancer Ther
, vol.4
, pp. 289-302
-
-
Prochownik, E.V.1
-
48
-
-
84859563192
-
Expression of caspase-3 and c-myc in non-small cell lung cancer
-
Yoo J, Kim CH, Song SH, et al. Expression of caspase-3 and c-myc in non-small cell lung cancer. Cancer Res Treat. 2004; 36: 303-307.
-
(2004)
Cancer Res Treat
, vol.36
, pp. 303-307
-
-
Yoo, J.1
Kim, C.H.2
Song, S.H.3
-
49
-
-
78549269168
-
miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc
-
Chen Z, Zheng H, Guo Y, et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res. 2010; 29:151.
-
(2010)
J Exp Clin Cancer Res
, vol.29
, pp. 151
-
-
Chen, Z.1
Zheng, H.2
Guo, Y.3
|